Patricia Inacio, PhD,  science writer—

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

Simple Blood Test May Become Useful Biomarker of Alzheimer’s Progression and Treatment Response, Study Suggests

Blood levels of a nerve cell-derived component, known as neurofilament light chain, could be used as a biomarker of disease severity and treatment response in patients with Alzheimer’s disease, a study suggests. The study, ”Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer’s Disease,” was published…

Cognitive Training Improves Reasoning and Memory in Adults with Mild Impairment, Pilot Study Finds

Cognitive training alone — without the use of direct brain stimulation — may significantly benefit adults with mild cognitive impairment, a known risk factor for Alzheimer’s disease, a pilot clinical study reports. The study, “Cognitive Training and Transcranial Direct Current Stimulation in Mild Cognitive Impairment: A Randomized Pilot Trial,”…

Investigational Azeliragon May Lessen Cognitive Decline in Mild Alzheimer’s Disease Patients with Type 2 Diabetes, Analysis Finds

The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from a subgroup analysis of the Phase 3 STEADFAST study. The findings were described in the presentation, “Inflammatory Biomarkers, Brain…

Dosing Starts in Phase 2 trial of Bryostatin-1 for Alzheimer’s

Neurotrope Bioscience announced that dosing of patients has started in its Phase 2 clinical trial to further evaluate Bryostatin-1, the company’s investigational candidate for the treatment of moderate to severe Alzheimer’s disease. “Completion of enrollment in our confirmatory Phase 2 trial is an important step toward understanding the transformative…